Skip to main content

Posts

Showing posts from July, 2019

Harvard scientist developed an algorithm that predicts protein 3D structure 1 million times faster than the latest algorithm.

Solving the 3D structure of a protein from amino acid sequences has been the mystery that has puzzled many scientists. With the advancement in AI, a biologist at Harvard have developed an algorithm which he claimed it will work 1 million times faster than Google’s AlphaFold, fastest protein structure predictor for the moment.

Prediction of Protein structure using the amino acid sequence has been the grandest quest, biologist of the world is trying to solve. The race to predict the structure from the amino acid sequence has intensified in the last decade. Many scientists using mathematical modeling, molecular biology, and computer science have developed many tools and algorithms to predict the correct structure with great efficiency and less time. AlphaFold is one of those, an algorithm developed by Google’s firm Deep mind that predicts proteins structure faster than the present techniques by at least 15%.

AlphaFold:  The algorithm uses neural networks to predict physical properties. I…

Top 5 public companies working on gene editing.

Top 5 public companies working on gene editing.
The ranking based on the revenues generated in 2018.


1.    Sangamo Therapeutics: $84.5million
 This is an American biotechnology company. They apply cell and gene therapy to combat hemophilia and other genetic diseases. They base the company in California, USA. They develop Zinc Finger gene-editing technology. Clinical trials involving gene editing using Zinc Finger Nuclease (ZFN) are ongoing.


2.    Horizon Discovery Group: $73.7m
It is a gene-editing company that designs and engineers genetically modified cells and then applies them in research and clinical applications that advance human health. They used three gene-editing tools CRISPR, ZFN, and recombinant Adeno-associated virus (rAAV). The company saw a 68% rise in revenue. The revenue was  £58.7million and based in Waterbeach, United Kingdom.


3.    Editas Medicine: $31.9m
It is a pharmaceutical company that aims to develop therapies based on CRISPR-CAS9 gene therapy. On 30th Nov 20…

ZFP-TFs gene regulation technology designed by Sangamo therapeutics could repressed allele specific gene without affecting the normal allele.

Sangamo therapeutics on July 1 announced publication of a manuscript in Nature Medicine on the activity of allele-specific Zinc Finger Proteins (ZFP-TFs) in models of Huntington’s Disease. The data which was published online on July 1 will appear in the July 2019 issue of Nature Medicine.
Scientists from Sangamo and its collaborators from CHDI foundation have used Zinc Finger Proteins Transcriptions Factors (ZFP-TFs) to selectively targets mutant allele of the Huntington gene (HTT) and repress its expression 99% while retaining 86% of the normal allele.
Huntington is a fatal, progressive, neurodegenerative disorder caused by a dominant mutation involving the expansion of CAG trinucleotide repeat in exon 1 of theHTT gene. Fully penetrant disease alleles of mutant HTT have more than 39 CAG repeats, but most HD patients have one healthy wild-type copy of HTT with less than 22 CAG repeats. Sangamo scientist has developed ZFP-TFs which could bind only to the mutant allele avoiding the normal…